---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018779"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:54:44.734107+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q1 2023: cash $533.6M; collaboration revenue $17.9M; net loss $27.3M

## Summary
- Cash, cash equivalents and marketable securities $533.6M; expected to fund through BLA filing in H1 2025.
- Collaboration revenue $17.9M from Kite license agreement (vs $0); recognized on percentage-of-completion basis.
- R&D expenses $32.9M (up $14.8M), G&A $15.4M (up $7.4M); net loss $27.3M (vs $26.0M).
- Clinical milestones: completing iMMagine-1 enrollment, initiating iMMagine-2, and presenting longer-term Phase 1 data for CART-ddBCMA.

## SEC filing metadata
- accession: 0000950170-23-018779
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000095017023018779/0000950170-23-018779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000095017023018779/aclx-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018779
- JSON: https://secwatch.observer/filing/0000950170-23-018779.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018779.txt

## Key facts
- Earnings Releases
  Arcellx, Inc. reported the first quarter ended March 31, 2023 results: revenue $17.9 million, net income $27.3 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $17.9 million
  - Net income: $27.3 million
  - Result: reported results
  source text: First Quarter 2023 Financial Highlights Cash, cash equivalents, and marketable securities: As of March 31, 2023, Arcellx had cash, cash equivalents, and marketable securities of $533.6 million. Arcellx expects that the cash, cash equivalents, and marketable securities on hand, will fund its operations through BLA filing of CART-ddBCMA planned for the first half of 2025 Collaboration revenue: Collaboration revenue was $17.9 million and zero for the quarters ended March 31, 2023 and 2022, respectively. The revenue results for the three months ended March 31, 2023 is from the recognition of research and development performed under the arrangement described in the recent license and collaboration agreement with Kite Pharma, Inc. (Kite). Revenue is being recognized on a percentage of completion basis over the term of the contract with Kite. R&D expenses: Research and development expenses were $32.9 million and $18.1 million for the quarters ended March 31, 2023 and 2022, respectively, an in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000095017023018779/0000950170-23-018779-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.